Volume 8 Supplement 1

5th European Workshop on Immune-Mediated Inflammatory Diseases

Open Access

Interstitial lung disease in patients with scleroderma - Treatment with rituximab

  • A Muñoz1,
  • R Martínez1,
  • S Rodríguez1,
  • M L Velloso1 and
  • J L Marenco1
Journal of Translational Medicine20108(Suppl 1):P45

https://doi.org/10.1186/1479-5876-8-S1-P45

Published: 25 November 2010

Introduction

Interstitial Lung Disease (ILD) is a severe complication of systemic sclerosis, more common among patients with diffuse scleroderma. Cyclophosphamide (CYC) is the treatment normally used in those patients, with irregular response. We have successfully treated 3 patients refractory to CYC with Rituximab (RTX).

Patients and methods

- Patient 1: A 43 years-old woman developed progressive cough and dyspnea, with radiological changes of interstitial lung disease. She began treatment with oral glucocorticoids and monthly boluses of CYC (1g i.v).

- Patient 2: A 53 years-old woman with a diagnosis of diffuse scleroderma three years earlier, started with dyspnea during low strain at the beginning. ILD was diagnosed with characteristic ground glass pattern on thoracic CT. She was given 6 boluses of CYC and oral glucocorticoids

- Patient 3: A 48 years-old women, with skin lesions suggestive of dermatomyositis (DM). In 2007 she was diagnosed of amyopathic DM with scleroderma overlap. Three 3 months after the diagnosis, she began with cough and dry expectoration, together with dyspnea. ILD was diagnosed with characteristic ground glass pattern on thoracic CT. She was initially treated monthly with CYC for 7 months. All patients, we started a treatment with RTX (2x1g) plus CYC.

Results

Respiratory function tests showed improvements (See table 1).

Table 1

 

Pat.1. Pre-RTX

Pat.1. Post-RTX

Pat.2. Pre-RTX

Pat.2. Post-RTX

Pat. 3. Pre-RTX

Pat.3. Post-RTX

Vital Cap (L)

1.94 (65.2%)

2.02 (68.5%)

1.08 (44.8%)

1.15 (48.3%)

1.43 (53.4%)

1.51 (56.7%)

FEV 1

1.75 (68.6%)

1.81 (71.6%)

1.08 (53.1%)

1.09 (54.5%)

1.12 (49.2%)

1.18 (52.2%)

FEV1/VC

90.35

89.69

99.91

94.86

78.38

78.15

TLCOc/VA (mol/min/Kpa)

1.20 (68%)

1.03 (59.2%)

0.93 (54.8%)

1.02 (60.6%)

1.20 (68.0%)

1.29 (73,8%)

PCO2 (mmHg)

44.1

42.8

32.6

40.2

33

35.1

PO2 (mmHg)

83

86

84

92

64

75

Sat O2 (%)

94.2

96.6

96.7

97.4

94.4

96.3

Conclusions

Overexpression of B lymphocytes in Scleroderma pathogenesis, and the bad evolution of ILD in those patients aimed us to try RTX (anti CD-20) after CYC failure. We have observed clinical improvement with respiratory test (table 1) without progression in lung CT changes. Further studies would be necessary to establish this therapeutic approach.

Authors’ Affiliations

(1)
Rheumatology, Valme University Hospital

Copyright

© Muñoz et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement